WallStSmart

Forian Inc (FORA)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 8665% more annual revenue ($2.46B vs $28.11M). RCM leads profitability with a -2.5% profit margin vs -3.0%. FORA appears more attractively valued with a PEG of 0.94. RCM earns a higher WallStSmart Score of 39/100 (F).

FORA

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 5.0

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 6.7Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FORA3 strengths · Avg: 8.7/10
Revenue GrowthGrowth
65.6%10/10

Revenue surging 65.6% year-over-year

PEG RatioValuation
0.948/10

Growing faster than its price suggests

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

FORA4 concerns · Avg: 2.3/10
Market CapQuality
$64.63M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-89.1%2/10

Earnings declined 89.1%

Free Cash FlowQuality
$-439,6662/10

Negative free cash flow — burning cash

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : FORA

The strongest argument for FORA centers on Revenue Growth, PEG Ratio, Price/Book. Revenue growth of 65.6% demonstrates continued momentum. PEG of 0.94 suggests the stock is reasonably priced for its growth.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : FORA

The primary concerns for FORA are Market Cap, Return on Equity, EPS Growth.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

FORA profiles as a hypergrowth stock while RCM is a turnaround play — different risk/reward profiles.

FORA carries more volatility with a beta of 1.03 — expect wider price swings.

FORA is growing revenue faster at 65.6% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Bottom Line

FORA scores higher overall (39/100 vs 39/100) and 65.6% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Forian Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Forian Inc. provides a suite of software solutions, data management capabilities, proprietary data, and predictive analytics to optimize and measure operational, clinical, and financial performance for clients in the health and cannabis industries, as well as dispensaries. , cannabis growers, manufacturers, and distributors. The company is headquartered in Newtown, Pennsylvania.

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a leading provider of technology-enabled revenue cycle management services, specializing in optimizing the financial performance of healthcare organizations. By leveraging advanced analytics and industry expertise, R1 RCM delivers comprehensive solutions that streamline patient billing processes and enhance operational efficiencies across a diverse portfolio of clients, including hospitals and outpatient facilities. The company's innovative approach not only improves revenue capture but also elevates the patient experience, positioning R1 RCM as a key player in the evolving healthcare landscape. With a robust growth strategy focused on expanding its service offerings and market reach, R1 RCM is poised to capitalize on the increasing demand for effective revenue cycle solutions in the healthcare sector.

Want to dig deeper into these stocks?